Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

NCT07441512 is registered in ClinicalTrials.gov with Hu Hai as lead sponsor.

NCT NCT07441512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07441512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
Lead sponsor
Hu Hai
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 15, 2026
Completion date
March 15, 2028
Enrollment
26 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc, tnbc - triple-negative breast cancer